Joe Y. Chang/X
Mar 30, 2025, 16:56
Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC
Joe Chang, Director of the Stereotactic Ablative Radiotherapy Program at MD Anderson Cancer Center, shared a post on X:
“Optimal first-line treatment for EGFR-mutated mNSCLC?
- Tagrisso alone for most patients.
- Tagrisso plus chemo for high-risk patients (brain/liver mets or large size)
- Amivantamab: Ab EGFR and MET. Lazertinib: EGFR TK
Don’t forget: SABR plus Tagrisso for oligomets or oligoprogression.”
More posts featuring Joe Chang.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 14:35
Apr 1, 2025, 14:08
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16